Protocol Ledger

NCT04801797 · Phase II · ACTIVE NOT RECRUITING

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Interventional Phase II clinical trial protocol NCT04801797 sponsored by Massachusetts General Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-20 Enrollment: 172 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04801797
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)172 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04801797
Protocol FieldVerified Registry Value
NCT IdentifierNCT04801797
Consolidated Lead SponsorMassachusetts General Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment172 participants (ESTIMATED)
Registered Start Date2021-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mass General Brigham across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI